The SET gene is a target of chromosomal translocations in acute leukemia and encodes a widely expressed multifunctional phosphoprotein. It has been shown that SET is upregulated in BCR-ABL1-positive cell lines, patient-derived chronic myeloid leukemia CD34-positive cells, and some solid tumors.
Methods and study design
We determined the expression level of SET in 59 pediatric acute lymphoblastic leukemia patients who were BCR-ABL-negative using quantitative real-time reverse-transcriptase-polymerase chain reaction.
Results
We showed that SET expression was significantly upregulated in 96.5% of B-acute lymphoblastic leukemia (28 of 29; 16.6 fold) and 93% of T-acute lymphoblastic leukemia (28 of 30; 47.6 fold) patients. This upregulation was not associated with any clinical features or overall and relapse-free survival.
Conclusions
Our results showed that SET is significantly overexpressed in pediatric acute lymphoblastic leukemia samples, and an increased level of SET might contribute to leukemic process.
RaimondiS.C.: Cytogenetics of acute leukemias. In: Childhood Leukemias, PuiCH, Ed, pp 235–271, Cambridge University Press, Cambridge, 2006.
4.
MulliganC.G.: Genomic analysis of acute leukemia. Int J Lab Hematol, 4: 384–397, 2009.
5.
Collins-UnderwoodJ.R., MulliganC.G.: Genomic profiling of high risk acute lymphoblastic leukemia. Leukemia, 24: 1676–1685, 2010.
6.
NagataK., KawaseH., HandaH., YanoK., YamasakiM., IshimiY., OkudaA., KikuchiA., MatsumotoK.: Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis. Proc Natl Acad Sci USA, 92: 4279–4283, 1995.
7.
Miyaji-YamaguchiM., OkuwakiM., NagataK.: Coiled-coil structure-mediated dimerization of template activating factor-I is critical for its chromatin remodeling activity. J Mol Biol, 290: 547–557, 1999.
8.
SeoS.B., MacNamaraP., HeoS., TurnerA., LaneW.S., ChakravartiD.: Regulation of histon acetylation and transcription by INHAT, a human cellular compex containing the SET oncoprotein. Cell, 104: 119–130, 2001.
9.
MoritaA., SuzikiN., MatsumatoY., HiranoK., EnomotoA., ZhuJ., SakaiK.: P41 as a possible marker for cell death is generated by caspase cleavage of p42 SET beta in irradiated MOLT-4 cells. Biochem Biophys Res Commun, 278: 627–632, 2000.
10.
FanZ., BaresfordP.J., OhD.Y., ZhangD., and LiebermanJ.: Tumor suppressor NM23-H1 is a granzyme-A activated DNase during CTL mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell, 112: 659–672, 2003.
11.
LiM., MakkinjeA., DamuniZ.: The myeloid leukemia associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem, 271: 11059–11062, 1996.
12.
CanelaN., Rodrigez-VilarruplaA., EstanyolJ.M., DiazC., PujolM.J., AngellN., BachsO.: The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase B activity. J Biol Chem, 278: 1158–1164, 2003.
CompagnoneNA., ZhangP., VigneJ.L., MellonS.H.: Novel role for nuclear phosphoprotein SET in transcriptional activation of p450c17 and initiation of neurosteroidogenesis. Mol Endocrinol, 14: 875–888, 2000.
15.
BrennanC.M., GallouziI.E., SteitzJ.A.: Protein ligands to HuR modulate its interaction with target mRNAs in vivo. J Cell Biol, 151: 1–14, 2000.
16.
AdachiY., PavlakisG.N., CopelandT.D.: Identification of in vivo phosphorylation sites of SET, a nuclear phosphoprotein encoded by the translocation breakpoint in acute undifferentiated leukemia. FEBS Lett, 340: 231–235, 1994.
17.
von LindernM., BreemsD., van BaalS., AdriaansenH., GrosveldG.: Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer, 5: 227–234, 1992.
KimJ., LeeS.G., SongJ., KimS.J., RhaS.Y., LeeK.A., ParkT.S., ChoiJ.R.: Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia. Cancer Genet Cytogenet, 201: 73–80, 2010.
20.
NevianiP., SanthanamR., TrottaR., NotariM., BlaserB.W.: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell, 8: 355–368, 2005.
21.
CarlsonS.G., EngE., KimE.G., PerlmanE.J., KopelandT.D., BallermannB.J.: Expression of SET an inhibitor of protein phosphatase 2A in renal development and Wilms’ tumor. J Am Soc Nephrol, 9: 1873–1880, 1998.
22.
FukukawaC., ShimaH., TanumaR., OgawaK., KikuchiK.: Up-regulation of I2PP2A/SET gene expression in rat primary hepatomas and regenerating livers. Cancer Lett, 161: 89–95, 2000.
23.
ChristensenD.J., BondK.M., VolkheimerA.D., OddoJ., ChenY., GockermanJ.P., MooreJ.O., DiehL.F., de CastroC.M., VitekM.P., WeinbergJ.B.: The SET oncogene, a potent PP2A inhibitor, is elevated in CLL and antagonism of SET induces apoptosis. 51th ASH Annual Meeting and Exposition. Blood, 104: 802, 2009 (abstract).
24.
SwitzerC.H., ChengR.Y., VitekT.M., ChristensenD.J., WinkD.A., VitekM.P.: Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene30(22): 2504–2513, 2011. Epub 2011 Feb 7.
